Compare UTZ & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UTZ | JANX |
|---|---|---|
| Founded | 2018 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.0B |
| IPO Year | 2018 | 2021 |
| Metric | UTZ | JANX |
|---|---|---|
| Price | $14.30 | $18.33 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 10 | 18 |
| Target Price | $14.31 | ★ $36.24 |
| AVG Volume (30 Days) | ★ 1.3M | 824.8K |
| Earning Date | 10-29-2026 | 11-05-2026 |
| Dividend Yield | ★ 1.76% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,438,800,000.00 | $10,000,000.00 |
| Revenue This Year | $3.71 | $194.24 |
| Revenue Next Year | $1.08 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 2.09 | N/A |
| 52 Week Low | $6.78 | $12.12 |
| 52 Week High | $14.33 | $35.34 |
| Indicator | UTZ | JANX |
|---|---|---|
| Relative Strength Index (RSI) | 73.17 | 60.72 |
| Support Level | $14.21 | $13.00 |
| Resistance Level | $14.33 | $19.14 |
| Average True Range (ATR) | 0.02 | 0.85 |
| MACD | -0.03 | 0.19 |
| Stochastic Oscillator | 81.82 | 81.92 |
Utz Brands Inc is a manufacturer of branded salty snacks based in the United States. It produces various salty snack foods, including potato chips, tortilla chips, pretzels, cheese snacks, party mixes, pork skins, ready-to-eat popcorn, and other snacks, which include salsa and dips. These products are offered through its flagship brands like Utz, On The Border, Zapp's, and Boulder Canyon, along with other brands, including Golden Flake, Miguelito's, Hawaiian, Bachman, Tim's Cascade, Dirty Potato Chips, TGI Fridays, and Vitner's. The company's products are packaged in a variety of different sizes and configurations, ranging from individual packages to shareable bulk containers. It also sells certain third-party branded products through its distribution network.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. The proprietary technology of the company has enabled the development of distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr), Tumor Activated Immunomodulators (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms. The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.